These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 823053)

  • 21. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease.
    Uy HL; Reasner CA; Samuels MH
    Am J Med; 1995 Aug; 99(2):173-9. PubMed ID: 7625422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The hypothalamic-Pituitary thyroid axis: studies on the regulatory role of thyrotropin releasing hormone (TRH) (author's transl)].
    Hirooka Y
    Nihon Naibunpi Gakkai Zasshi; 1976 Sep; 52(9):908-25. PubMed ID: 828584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stimulation with thyrotrophin-releasing hormone (TRH) during antithyroid treatment.
    Lauridsen UB; Kirkegaard C; Friis T; Siersbaek-Nielsen K
    Acta Endocrinol (Copenh); 1975 Mar; 78(3):461-7. PubMed ID: 47216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
    Aizawa T; Ishihara M; Koizumi Y; Hashizume K; Takasu N; Yamada T; Kobayashi I; Watanabe T; Shimizu Z
    Am J Med; 1990 Aug; 89(2):175-80. PubMed ID: 2166430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism.
    Homsanit M; Sriussadaporn S; Vannasaeng S; Peerapatdit T; Nitiyanant W; Vichayanrat A
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):385-90. PubMed ID: 11298092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study of thyroid function after subtotal thyroidectomy for Graves' disease: particularly on TRH tests, T3 suppression tests and antithyroid antibodies in euthyroid patients.
    Fukino O; Tamai H; Fujii S; Ohsako N; Matsubayashi S; Kuma K; Nagataki S
    Acta Endocrinol (Copenh); 1983 May; 103(1):28-33. PubMed ID: 6407253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
    Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE
    J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to thyrotropin releasing hormone: an objective criterion for the adequacy of thyrotropin suppression therapy.
    Hoffman DP; Surks MI; Oppenheimer JH; Weitzman ED
    J Clin Endocrinol Metab; 1977 May; 44(5):892-901. PubMed ID: 404309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Follow up studies of the antithyroid drug therapy for hyperthyroidism with special emphasis on the clinical usefulness of TRH and T3-suppression tests during treatment (author's transl)].
    Tamai H
    Fukuoka Igaku Zasshi; 1978 Nov; 69(11):486-94. PubMed ID: 83955
    [No Abstract]   [Full Text] [Related]  

  • 33. Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism.
    Martino E; Pinchera A; Capiferri R; Macchia E; Sardano G; Bartalena L; Mazzanti F; Baschieri L
    J Clin Endocrinol Metab; 1976 Sep; 43(3):543-9. PubMed ID: 821960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Responses to TRH and T3 suppression tests in euthyroid subjects with a family history of Graves' disease.
    Tamai H; Suematsu H; Ikemi Y; Kuma K; Matsuzuka F; Kumagai LF; Shizume K; Nagataki S
    J Clin Endocrinol Metab; 1978 Sep; 47(3):475-9. PubMed ID: 122407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical studies on regulatory system of thyroid hormone secretion and serum triiodothyronine. Part II. Development of rapid radioimmunoassay for triiodothyronine (author's transl)].
    Takeda Y
    Nihon Naibunpi Gakkai Zasshi; 1975 Jan; 51(1):36-47. PubMed ID: 807488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of hypothyroidism on hypothalamic release of thyrotropin-releasing hormone in rats.
    Rondeel JM; de Greef WJ; Klootwijk W; Visser TJ
    Endocrinology; 1992 Feb; 130(2):651-6. PubMed ID: 1733713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid vascular conductance: differential effects of elevated plasma thyrotropin (TSH) induced by treatment with thioamides or TSH-releasing hormone.
    Connors JM; Huffman LJ; Michalkiewicz M; Chang BS; Dey RD; Hedge GA
    Endocrinology; 1991 Jul; 129(1):117-25. PubMed ID: 1905224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of patients with normal T3 and T4 and a low TSH response to TRH.
    Boutin JM; Matte R; D'Amour P; Gilbert F; Havrankova J; Bélanger R; Chartrand R; Zakarija M
    Clin Endocrinol (Oxf); 1986 Nov; 25(5):579-88. PubMed ID: 2887310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.